Compare DraftKings Inc (DKNG) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DraftKings Inc vs Sana Biotechnology Inc — how do they compare? DraftKings Inc trades at $19.58 (market cap $9.86B), while Sana Biotechnology Inc trades at $2.81 (market cap $836.71M). The key difference: DraftKings Inc is far larger — about 11.8× Sana Biotechnology Inc's market cap, and DraftKings Inc is more actively traded (16,584,596 versus 4,507,444). Which is the better fit depends on your goals — on Pluang, investors hold DraftKings Inc for 55 Days and Sana Biotechnology Inc for 23 Days on average.
| DKNG | SANA | |
|---|---|---|
Market Cap | $9.86B | $836.71M |
Volume | 16,584,596 | 4,507,444 |
Sector | Consumer Cyclical | Health |
52-Week High | $36.24 | $5.92 |
52-Week Low | $18.59 | $2.68 |
Typical Hold Time | 55 Days | 23 Days |
Enterprise Value | $10.80B | $749.96M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DraftKings (DKNG) trades at $19.43, down 1.46% on the day and near 52-week lows. The technical picture is bearish with weak moving averages, while fundamentals show strong revenue growth to $6.05B in 2025 but negative profitability metrics. Recent earnings misses and high valuation multiples create headwinds, though analyst sentiment remains overwhelmingly bullish with a $33.13 price target.
The stock faces near-term pressure from technical weakness and earnings volatility, but long-term prospects are supported by market share leadership and prediction platform expansion. Key risks include competitive threats, regulatory uncertainty, and the sustainability of current valuation levels amid profitability challenges.
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DraftKings Inc
DraftKings Inc is a digital sports entertainment and gaming company. The company provides users with daily fantasy sports (DFS), sports betting, and iGaming opportunities and is also involved in the design & development of sports betting and casino gaming platform software for online and retail sportsbook and casino gaming products. It operates in two segments: Business-to-consumer(B2C) and Business-to-Business(B2B), of which the vast majority of its revenue comes from the B2C segment. Geographically, it derives most of its revenue from the United States.
Read more on DKNG →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
